Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Celgene's Enterprise Value is ARS4,605,377.62 Mil.
Celgene's EBIT for the trailing twelve months (TTM) ended in Sep. 2019 was ARS335,469.89 Mil. Therefore, Celgene's EV-to-EBIT ratio for today is 13.73.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Celgene's Enterprise Value is ARS4,605,377.62 Mil.
Celgene's EBITDA for the trailing twelve months (TTM) ended in Sep. 2019 was ARS364,639.50 Mil. Therefore, Celgene's EV-to-EBITDA ratio for today is 12.63.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Celgene's Enterprise Value is ARS4,605,377.62 Mil.
Celgene's Revenue for the trailing twelve months (TTM) ended in Sep. 2019 was ARS758,925.46 Mil. Therefore, Celgene's EV-to-Revenue ratio for today is 6.07.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Celgene's Enterprise Value is ARS4,605,377.62 Mil.
Celgene's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2019 was ARS329,083.92 Mil. Therefore, Celgene's EV-to-FCF ratio for today is 13.99.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Celgene (BUE:CELG) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Celgene's current Enterprise Value is ARS4,605,377.62 Mil.
Celgene's EBIT for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS335,469.89 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Celgene's current Enterprise Value is ARS4,605,377.62 Mil.
Celgene's EBITDA for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS364,639.50 Mil.
Celgene's current Enterprise Value is ARS4,605,377.62 Mil.
Celgene's Revenue for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS758,925.46 Mil.
Celgene's current Enterprise Value is ARS4,605,377.62 Mil.
Celgene's Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS364,330.33 Mil.
Celgene's current Enterprise Value is ARS4,605,377.62 Mil.
Celgene's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS329,083.92 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celgene Enterprise Value Related Terms
Celgene Enterprise Value Historical Data
* Premium members only.
The historical data trend for Celgene's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BUE:CELG vs GILD, BIIB, ACT: Enterprise Value Comparison
For the Drug Manufacturers - General subindustry, Celgene's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celgene Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Celgene's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Celgene's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Celgene's Enterprise Value for the fiscal year that ended in Dec. 2018 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of ARS4,605,377.62 Mil mean?
Celgene (BUE:CELG) has a Enterprise Value of ARS4,605,377.62 Mil as of Jul. 08, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Celgene and its competitors.
Is Celgene's Enterprise Value too high?
Celgene's current Enterprise Value is ARS4,605,377.62 Mil. Overall, Celgene has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Celgene's Enterprise Value compare to GILD and BIIB?
Celgene's Enterprise Value of ARS4,605,377.62 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Celgene and its competitors. Celgene's current Enterprise Value is ARS4,605,377.62 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celgene stock overvalued right now?
Celgene (BUE:CELG) has a current Enterprise Value of ARS4,605,377.62 Mil. The current Enterprise Value is ARS4,605,377.62 Mil. Celgene's overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Celgene (BUE:CELG), the current Enterprise Value is ARS4,605,377.62 Mil as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Pending acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUE:CELG has been successfully added to your 